Aortic Stenosis and Cardiac Amyloidosis

Summary

The dual pathology of aortic stenosis (AS) and cardiac amyloidosis (CA) is increasingly recognized. Even tough efforts have been undertaken to bring cohorts together, the largest cohort of AS-ATTR to date is \<50 patients. It is the aim of the present international, multi-center registry to collect \~300 patients with AS-CA creating a big enough cohort to allow

1. thorough characterization of this condition
2. assessment of log-term clinical outcomes of AS-CA
3. assessment of effectiveness of amyloid-specific treatment on top of valve replacement

Conditions

• Cardiac Amyloidosis
• Aortic Stenosis

Interventions

DRUG

Amyloid-specific treatment

Amyloid-specific treatment

OTHER

No amyloid-specific treatment

No amyloid-specific treatment

Sponsors & Collaborators

• Allina Health System

  collaborator OTHER

• Royal Free Hospital NHS Foundation Trust

  collaborator OTHER

• Columbia University

  collaborator OTHER

• Medical University of South Carolina

  collaborator OTHER

• Laval University

  collaborator OTHER

• Vilnius University Hospital Santaros Klinikos

  collaborator OTHER

• Université Catholique de Louvain

  collaborator OTHER

• Wolfson Medical Center

  collaborator OTHER_GOV

• IRCCS Azienda Ospedaliero-Universitaria di Bologna

  collaborator OTHER

• University of Trieste

  collaborator OTHER

• Medical University of Vienna

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-03-01

Primary Completion

2024-12-31

Completion

2024-12-31

Countries

• Austria
• United Kingdom

Study Locations